The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome
Φόρτωση...
Ημερομηνία
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Atherosclerosis
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: Increased concentration of small dense LDL cholesterol (sdLDL-C) and activity of lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are considered as emerging cardiovascular risk factors and are commonly encountered in subjects with metabolic syndrome (MetS). OBJECTIVE: The primary endpoint of this study was the effect of orlistat and fenofibrate, alone or in combination, on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients (body mass index>28 kg/m(2)) with MetS. METHODS: Patients (n=89) were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200mg/day (F group) or both (OF group) for 6 months. RESULTS: Significant reductions of sdLDL-C levels were observed in all treatment groups. Groups F and OF experienced a greater reduction in sdLDL-C levels (p<0.05) together with a greater increase in LDL particle diameter (p<0.05) compared with group O. Total plasma Lp-PLA(2) activity significantly decreased in all treatment groups. The reduction of Lp-PLA(2) was more pronounced with OF administration compared with each monotherapy (p<0.05). CONCLUSION: Orlistat and fenofibrate exhibited favorable effects on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients with MetS. Importantly, combination treatment had a more favorable effect on these risk factors.
Περιγραφή
Λέξεις-κλειδιά
1-Alkyl-2-acetylglycerophosphocholine Esterase/*blood, Adult, Anti-Obesity Agents/pharmacology/therapeutic use, Cardiovascular Diseases/drug therapy/etiology, Cholesterol, LDL/*blood, Drug Therapy, Combination, Female, Fenofibrate/pharmacology/*therapeutic use, Humans, Hypolipidemic Agents/pharmacology/therapeutic use, Lactones/pharmacology/*therapeutic use, Male, Metabolic Syndrome X/drug therapy/etiology, Middle Aged, Obesity/complications/*drug therapy, Overweight, Phospholipases A2, Risk Factors
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/16911813
http://ac.els-cdn.com/S0021915006004084/1-s2.0-S0021915006004084-main.pdf?_tid=d29956a44a96251d298a203a6bbb2079&acdnat=1333531139_a7897d9d8d05921b4cdc9ffe783e74bc
http://ac.els-cdn.com/S0021915006004084/1-s2.0-S0021915006004084-main.pdf?_tid=d29956a44a96251d298a203a6bbb2079&acdnat=1333531139_a7897d9d8d05921b4cdc9ffe783e74bc
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής